retatrutide phase 2 trial type 2 diabetes results 2024 💉 may be redefining obesity treatment. New data from TRIUMPH-1 showed: 🔥 ~28% average weight loss over 80 weeks 🔥 >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic Retatrutide produces up to 30.3%

Caveolin-1 knockout mice also fail to properly liberate fatty acids from TAG stores in brown adipose tissue in response to fasting, resulting in impaired thermogenesis (24)

One way to interpret this figure is to select a change in body weight of interest on the horizontal axis and note the corresponding proportions of patients (vertical axis) in each treatment group who achieved at least that degree of weight loss

HFD-fed obese mice responded to p.o

These findings collectively indicate that modulation of the gut microbiotaSCFAGPR axis plays a pivotal role in alleviating DN-associated renal fibrosis, supporting its potential as a microbiota-targeted therapeutic strategy for improving renal outcomes in DN